Used as a potent carbonic anhydrase inhibitor, this compound shows significant potential in the treatment of glaucoma by reducing intraocular pressure. It selectively inhibits carbonic anhydrase II and IX isoforms, making it valuable in both ophthalmic applications and cancer research, particularly in hypoxic tumor environments where CA-IX is overexpressed. Its sulfonamide group enhances binding to the enzyme's active site, contributing to high efficacy at low concentrations. Additionally, due to its lipophilic nature imparted by the trifluoromethyl and aromatic groups, it exhibits good tissue penetration and bioavailability, supporting its use in therapeutic settings.